CoChat

Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians

Qaseem, Amir, Forciea, Mary Ann, McLean, Robert M., Denberg, Thomas D., for the Clinical Guidelines Committee of the American College of Physicians* · 2017 · Annals of Internal Medicine

The DOI matches its Crossref record; 370 of the 370 references it cites were found in a registry or an index.

Abstract

Description: This guideline updates the 2008 American College of Physicians (ACP) recommendations on treatment of low bone density and osteoporosis to prevent fractures in men and women. This guideline is endorsed by the American Academy of Family Physicians. Methods: The ACP Clinical Guidelines Committee based these recommendations on a systematic review of randomized controlled trials; systematic reviews; large observational studies (for adverse events); and case reports (for rare events) that were published between 2 January 2005 and 3 June 2011. The review was updated to July 2016 by using a machine-learning method, and a limited update to October 2016 was done. Clinical outcomes evaluated were fractures and adverse events. This guideline focuses on the comparative benefits and risks of short- and long-term pharmacologic treatments for low bone density, including pharmaceutical prescriptions, calcium, vitamin D, and estrogen. Evidence was graded according to the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. Target Audience and Patient Population: The target audience for this guideline includes all clinicians. The target patient population includes men and women with low bone density and osteoporosis. Recommendation 1: ACP recommends that clinicians offer pharmacologic treatment with alendronate, risedronate, zoledronic acid, or denosumab to reduce the risk for hip and vertebral fractures in women who have known osteoporosis. (Grade: strong recommendation; high-quality evidence). Recommendation 2: ACP recommends that clinicians treat osteoporotic women with pharmacologic therapy for 5 years. (Grade: weak recommendation; low-quality evidence). Recommendation 3: ACP recommends that clinicians offer pharmacologic treatment with bisphosphonates to reduce the risk for vertebral fracture in men who have clinically recognized osteoporosis. (Grade: weak recommendation; low-quality evidence). Recommendation 4: ACP recommends against bone density monitoring during the 5-year pharmacologic treatment period for osteoporosis in women. (Grade: weak recommendation; low-quality evidence). Recommendation 5: ACP recommends against using menopausal estrogen therapy or menopausal estrogen plus progestogen therapy or raloxifene for the treatment of osteoporosis in women. (Grade: strong recommendation; moderate-quality evidence). Recommendation 6: ACP recommends that clinicians should make the decision whether to treat osteopenic women 65 years of age or older who are at a high risk for fracture based on a discussion of patient preferences, fracture risk profile, and benefits, harms, and costs of medications. (Grade: weak recommendation; low-quality evidence).

Overview

Integrity signals

Registry

Crossref · 10.7326/m15-1361

Cites

370 of 370 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

9 retracted

Research works printed but not linked: 25

  1. Bonnick S, 1998, Bone, 23, S476
  2. 10.1210/jcem.85.2.6393 · doi:10.1210/jcem.85.2.6393 · Paper page
  3. 10.1185/030079903125002009 · DOI
  4. McClung M, 1998, Osteoporos Int, 8, 111
  5. Chao M, 2013, Pak J Med Sci, 29, 1381
  6. Lippuner K, 2013, Osteoporosis Int, 24, S39
  7. Palacios S, 2013, Osteoporosis Int, 24, S299
  8. Papapoulos S, 2013, Osteoporosis Int, 24, S45
  9. 10.1359/jbmr.2003.18.1.9 · DOI · Paper page
  10. 10.1210/jcem.85.9.6836 · doi:10.1210/jcem.85.9.6836 · Paper page
  11. Adachi JD, 1996, J Rheumatol, 23, 995
  12. Aloia JF, 1985, J Lab Clin Med, 106, 630
  13. Caniggia A, 1984, Acta Vitaminol Enzymol, 6, 117
  14. Geusens P, 1986, Bone Miner, 1, 347
  15. Jensen GF, 1985, Clin Orthop Relat Res, 215
  16. Menczel J, 1994, Clin Orthop Relat Res, 241
  17. Orimo H, 1987, Bone Miner, 3, 47
  18. Muscoso E, 2004, Eur Rev Med Pharmacol Sci, 8, 97
  19. Migliore A, 2013, Eur Rev Med Pharmacol Sci, 17, 658
  20. Almăşan HA, 2011, Rom J Morphol Embryol, 52, 1233
  21. 10.1056/nejmoa011807 · DOI · Paper page
  22. Krohn K, 2014, Osteoporosis Int, 25, S61, 10.1007/s00198-013-2525-0 · DOI
  23. 10.1210/jcem.87.3.8325 · doi:10.1210/jcem.87.3.8325 · Paper page
  24. Zheng S, 2003, Chin Med J (Engl), 116, 1127
  25. Liu JL, 2004, Chin Med J (Engl), 117, 1029

Cited by

See all 741

Metadata

Authors
Qaseem, A., Forciea, M. A., McLean, R. M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians*
Affiliations
Yale University (US)
Venue
Annals of Internal Medicine
Published
2017-06-06
Volume
166
Issue
11
Pages
818-839
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2614075773
Cited by
676
References
368
Citations by year
2026: 33 · 2025: 53 · 2024: 65 · 2023: 85 · 2022: 82 · 2021: 81 · 2020: 95 · 2019: 75 · 2018: 70 · 2017: 35
FWCI
83.08
Type
journal article
Language
en
Open access
closed
Licence
www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
Locations
  • Annals of Internal Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
  • Health Sciences › Medicine › Oncology › Bone health and treatments
Keywords
osteoporosis, osteopenia, fracture prevention, pharmacotherapy, bisphosphonates, denosumab, zoledronic acid, risedronate, alendronate, hormone replacement therapy, raloxifene, calcium and vitamin D supplementation, treatment duration, hip fracture
MeSH terms
Denosumab, Bone Diseases, Metabolic, Calcium, Dietary, Diphosphonates, Female, Humans, Male, Osteoporosis, Risk Factors, Vitamin D, Exercise, Osteoporosis, Postmenopausal, Estrogen Replacement Therapy, Teriparatide, Raloxifene Hydrochloride, Fractures, Bone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.